JPWO2010047302A1 - Total nutritional fluid - Google Patents
Total nutritional fluid Download PDFInfo
- Publication number
- JPWO2010047302A1 JPWO2010047302A1 JP2010534800A JP2010534800A JPWO2010047302A1 JP WO2010047302 A1 JPWO2010047302 A1 JP WO2010047302A1 JP 2010534800 A JP2010534800 A JP 2010534800A JP 2010534800 A JP2010534800 A JP 2010534800A JP WO2010047302 A1 JPWO2010047302 A1 JP WO2010047302A1
- Authority
- JP
- Japan
- Prior art keywords
- solution
- vitamin
- infusion
- comprehensive
- further contains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 46
- 239000012530 fluid Substances 0.000 title 1
- 239000000243 solution Substances 0.000 claims abstract description 202
- 229940088594 vitamin Drugs 0.000 claims abstract description 36
- 229930003231 vitamin Natural products 0.000 claims abstract description 36
- 235000013343 vitamin Nutrition 0.000 claims abstract description 36
- 239000011782 vitamin Substances 0.000 claims abstract description 36
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 34
- 150000001413 amino acids Chemical class 0.000 claims abstract description 30
- 238000001802 infusion Methods 0.000 claims abstract description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 23
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000000346 sugar Nutrition 0.000 claims abstract description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 18
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 18
- 229960003495 thiamine Drugs 0.000 claims abstract description 17
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960002477 riboflavin Drugs 0.000 claims abstract description 16
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 16
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 15
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 15
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 13
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 13
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 13
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 12
- 239000011719 vitamin A Substances 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 229940045997 vitamin a Drugs 0.000 claims abstract description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 11
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 11
- 239000010949 copper Substances 0.000 claims abstract description 11
- 229910052802 copper Inorganic materials 0.000 claims abstract description 11
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 11
- 239000011710 vitamin D Substances 0.000 claims abstract description 11
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 11
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 11
- 239000011712 vitamin K Substances 0.000 claims abstract description 11
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 11
- 229940046008 vitamin d Drugs 0.000 claims abstract description 11
- 229940046010 vitamin k Drugs 0.000 claims abstract description 11
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 10
- 229930003756 Vitamin B7 Natural products 0.000 claims abstract description 9
- 229910052742 iron Inorganic materials 0.000 claims abstract description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 9
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 9
- 235000011912 vitamin B7 Nutrition 0.000 claims abstract description 9
- 239000011735 vitamin B7 Substances 0.000 claims abstract description 9
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 8
- 150000002948 pantothenic acids Chemical class 0.000 claims abstract description 7
- 239000011630 iodine Substances 0.000 claims description 36
- 235000013675 iodine Nutrition 0.000 claims description 36
- 229910052740 iodine Inorganic materials 0.000 claims description 36
- 239000003978 infusion fluid Substances 0.000 claims description 30
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 26
- 239000003792 electrolyte Substances 0.000 claims description 24
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 230000035764 nutrition Effects 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 15
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 11
- 235000019152 folic acid Nutrition 0.000 claims description 11
- 239000011724 folic acid Substances 0.000 claims description 11
- 229960000304 folic acid Drugs 0.000 claims description 11
- 238000005192 partition Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 235000001968 nicotinic acid Nutrition 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 7
- 229930003779 Vitamin B12 Natural products 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 7
- 239000011574 phosphorus Substances 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 235000019163 vitamin B12 Nutrition 0.000 claims description 7
- 239000011715 vitamin B12 Substances 0.000 claims description 7
- 150000002814 niacins Chemical class 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 235000019157 thiamine Nutrition 0.000 claims description 4
- 239000011721 thiamine Substances 0.000 claims description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229960002873 benfotiamine Drugs 0.000 claims description 3
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 3
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 claims description 3
- 229950006836 fursultiamine Drugs 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229960001385 thiamine disulfide Drugs 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 abstract description 27
- 235000013619 trace mineral Nutrition 0.000 abstract description 18
- 239000011573 trace mineral Substances 0.000 abstract description 18
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002358 iodine Drugs 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 26
- -1 iodine ions Chemical class 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 17
- 239000007789 gas Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 239000005022 packaging material Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 6
- 229940123973 Oxygen scavenger Drugs 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 229910001431 copper ion Inorganic materials 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940037395 electrolytes Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 229940101267 panthenol Drugs 0.000 description 3
- 235000020957 pantothenol Nutrition 0.000 description 3
- 239000011619 pantothenol Substances 0.000 description 3
- 229920002239 polyacrylonitrile Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 3
- 239000011747 thiamine hydrochloride Substances 0.000 description 3
- 238000007740 vapor deposition Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000012611 container material Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 235000012711 vitamin K3 Nutrition 0.000 description 2
- 239000011652 vitamin K3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910001567 cementite Inorganic materials 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000009491 menaquinone-4 Nutrition 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- 229960005481 menatetrenone Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- MOGXONWQXZGYTK-UHFFFAOYSA-N pyridine-3-carboxylic acid;sodium Chemical compound [Na].OC(=O)C1=CC=CN=C1 MOGXONWQXZGYTK-UHFFFAOYSA-N 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
長期間安定にビタミン類及び微量元素を含有する総合栄養輸液剤を提供する。連通可能な隔壁で隔てられた4室容器に、還元糖、ビタミンB1類及びビタミンB6を含有した溶液A、アミノ酸、ビタミンB2及びパントテン酸類を含有した溶液B、ビタミンA、ビタミンD、ビタミンE、ビタミンK、ビタミンC、ビタミンH及びヨウ素を含有した溶液C、鉄及び銅を含有した溶液Dを収容した総合栄養輸液剤とする。Provided is a comprehensive nutritional infusion containing vitamins and trace elements stably for a long period of time. Solution A containing reducing sugar, vitamin B1 and vitamin B6, solution B containing amino acids, vitamin B2 and pantothenic acids, vitamin A, vitamin D, vitamin E A comprehensive nutritional infusion containing a solution C containing vitamin K, vitamin C, vitamin H and iodine, and a solution D containing iron and copper.
Description
本発明は、還元糖、アミノ酸、電解質、ビタミン及び微量元素を配合し、加熱滅菌処理された総合栄養輸液剤に関する。 The present invention relates to a comprehensive nutritional infusion solution that is formulated by combining a reducing sugar, an amino acid, an electrolyte, a vitamin, and trace elements and is heat-sterilized.
近年、経静脈栄養療法は著しい進歩を遂げ、糖・電解質・アミノ酸を含有した輸液剤が汎用されている。しかし、経口栄養補給ができないで経静脈栄養輸液のみに頼る場合には、糖・電解質・アミノ酸の投与のみではビタミンや微量元素の欠乏症が生じる。また、ビタミンB1を投与せずに大量の糖負荷がかかると、糖代謝に大きな異常をきたし、重篤な副作用である乳酸アシドーシスを引き起こすことがある。そこで、医療現場では、糖・電解質・アミノ酸輸液にビタミン製剤や微量元素製剤が混注により用時添加されている。しかし、混注は操作が煩雑であり、誤投薬による医療過誤の危険性がある。また、混注操作により細菌汚染や異物混入が危惧され、医療事故の一因となることもある。そこで、還元糖、アミノ酸、電解質及びビタミンを含有し、無菌状態で溶液を混合できる製剤の開発が行われている。
例えば、特許文献1や、特許文献2にビタミンを配合した輸液剤が開示されている。
しかし、上記した従来技術によって、ビタミン類の安定性は向上するが、微量元素の含有が課題であり、その改良が求められている。例えば、輸液剤を酸素の影響を受けないよう脱酸素状態で保存した場合、銅イオンとヨウ素イオンを同じ室に収容すると沈殿が生じる。この対策として、特許文献3では、銅イオンとヨウ素イオンを別々に収容し、アミノ酸液及び/又は糖液にヨウ素イオンを含有する輸液剤が開示されている。この方法は、ヨウ素イオンが大容量の室に収容されるため、微量であるヨウ素の濃度が更に薄くなり、含量の測定に支障が生じる懸念がある。また、特許文献4では、ガスバリア性の室に銅イオンとヨウ素イオンを含有する薬液が酸素含有ガスと共に収容された輸液剤が開示されている。この方法は、酸素遮断性の材質が高価であり、また、酸素含有ガスと共に収容するため製造時の工程が煩雑になるなどコストアップが危惧される。In recent years, parenteral nutrition therapy has made remarkable progress, and infusions containing sugars, electrolytes, and amino acids have been widely used. However, vitamins and trace element deficiencies occur only by administration of sugars, electrolytes, and amino acids when oral nutritional supplementation is not possible and only the parenteral nutrition solution is relied upon. In addition, if a large amount of glucose load is applied without administering vitamin B1, a large abnormality is caused in sugar metabolism, which may cause lactic acidosis, which is a serious side effect. Therefore, in medical practice, vitamin preparations and trace element preparations are added to sugar, electrolyte and amino acid infusion solutions at the time of use. However, mixed injection is complicated in operation, and there is a risk of medical error due to incorrect medication. In addition, the mixed injection operation may cause bacterial contamination and foreign matter, which may contribute to medical accidents. Therefore, a formulation containing a reducing sugar, an amino acid, an electrolyte and a vitamin and capable of mixing the solution under aseptic conditions has been developed.
For example, Patent Document 1 and Patent Document 2 disclose an infusion agent containing vitamins.
However, although the above-described conventional techniques improve the stability of vitamins, the inclusion of trace elements is an issue, and there is a need for improvement. For example, when the infusion is stored in a deoxygenated state so as not to be affected by oxygen, precipitation occurs when copper ions and iodine ions are stored in the same chamber. As a countermeasure, Patent Document 3 discloses an infusion agent containing copper ions and iodine ions separately and containing iodine ions in an amino acid solution and / or a sugar solution. In this method, since iodine ions are accommodated in a large-capacity chamber, there is a concern that the concentration of iodine, which is a trace amount, is further reduced, and the measurement of the content is hindered. Patent Document 4 discloses an infusion agent in which a chemical solution containing copper ions and iodine ions is stored together with an oxygen-containing gas in a gas barrier chamber. In this method, the oxygen barrier material is expensive, and since it is housed together with the oxygen-containing gas, the manufacturing process becomes complicated and there is a concern that the cost will increase.
本発明は、還元糖、アミノ酸、電解質、ビタミン及び微量元素を含有し、ビタミン類及び微量元素が長期に安定な総合栄養輸液剤を提供するものである。還元糖、アミノ酸、電解質、ビタミン及び微量元素の各成分は、安定なpH領域が異なり、また相互作用を生じるものがあるため、考慮して各室への配合を設定する必要がある。特に微量元素を配合する場合、保存時の無酸素状態におけるヨウ素の含量低下を抑制する必要がある。更にその際に、品質管理のためのヨウ素の含量測定が困難とならないようにすることが必要である。 The present invention provides a comprehensive nutrition infusion solution containing reducing sugars, amino acids, electrolytes, vitamins and trace elements, wherein the vitamins and trace elements are stable for a long period of time. Reducing sugars, amino acids, electrolytes, vitamins, and trace elements have different stable pH ranges and may interact with each other, so it is necessary to set the composition in each chamber in consideration. In particular, when a trace element is blended, it is necessary to suppress a decrease in iodine content in an oxygen-free state during storage. At that time, it is necessary not to make it difficult to measure the iodine content for quality control.
鋭意検討した結果、ビタミンの安定性を保持しつつ、ヨウ素の含量低下をなくして微量元素を簡易に安定化する方法を見出した。更にこの方法ではヨウ素の含量測定も容易となる。すなわち、銅を鉄等の微量元素と配合し、ヨウ素を脂溶性ビタミンと配合することにより銅イオンとヨウ素イオンが共存することを避けたものである。本発明は、次の総合栄養輸液剤に関するものである。
1.溶液A、溶液B、溶液C及び溶液Dを連通可能な隔壁で隔てられた4室容器の各室に収容し、溶液Aが還元糖及びビタミンB1類を含有し、溶液Bがアミノ酸を含有し、溶液CがビタミンA、ビタミンD、ビタミンE、ビタミンKより選ばれる少なくとも1種類以上の脂溶性ビタミン及びヨウ素を含有し、溶液Dが銅を含有することを特徴とする総合栄養輸液剤。
2.溶液A、溶液B、溶液C及び溶液Dを連通可能な隔壁で隔てられた4室容器の各室に収容し、溶液Aが還元糖及びビタミンB1類を含有し、溶液Bがアミノ酸を含有し、溶液CがビタミンA、ビタミンD、ビタミンE、ビタミンKより選ばれる少なくとも1種類以上の脂溶性ビタミン及びヨウ素を含有し、溶液Dが鉄及び銅を含有し、更に溶液A及び/又は溶液B及び/又は溶液C及び/又は溶液Dが電解質を含有し、加熱滅菌処理されたことを特徴とする総合栄養輸液剤。
3.溶液Cが、更にビタミンCを含有し且つビタミンB2を含有しない、1又は2に記載の総合栄養輸液剤。
4.溶液Cが、ビタミンA、ビタミンD、ビタミンE、ビタミンK、ビタミンC、ビオチン、及び葉酸を含有し、かつ、ビタミンB2を含有しない、1又は2に記載の総合栄養輸液剤。
5.溶液C中のヨウ素の濃度が0.10 mmol/L〜0.25mmol/Lである1〜4のいずれかに記載の総合栄養輸液剤。
6.溶液Aが、更にリンとしてリン酸二カリウムを含む電解質を含有し、かつ、クエン酸を含有する1〜5のいずれかに記載の総合栄養輸液剤。
7.溶液Aが、更にビタミンB6、ビタミンB12及びニコチン酸類を含有し、溶液Bが更にビタミンB2及びパントテン酸類を含有し、溶液Cが、更にビタミンC、ビタミンH及び葉酸を含有する1〜6のいずれかに記載の総合栄養輸液剤。
8.溶液Aが更にビタミンB6及びビタミンB12を含有し、溶液Bが更にビタミンB2、パントテン酸類及びニコチン酸類を含有し、溶液Cが更にビタミンC、ビタミンH及び葉酸を含有する、1〜6のいずれかに記載の総合栄養輸液剤。
9.溶液Dが、更にマンガン及び亜鉛を含有する1〜8のいずれかに記載の総合栄養輸液剤。
10.電解質がナトリウム、カリウム、マグネシウム、カルシウム、クロル、リンより選ばれる少なくとも1種類以上である1〜9のいずれかに記載の総合栄養輸液剤。
11.ビタミンB1類がチアミン、チアミンジスルフィド、フルスルチアミン、ベンフォチアミン及びこれらの塩より選ばれる少なくとも1種類以上である1〜10のいずれかに記載の総合栄養輸液剤。
12.溶液AのpHが3〜6、溶液B、溶液C及び溶液DのpHが5〜8であり、溶液A、溶液B、溶液C及び溶液Dを混合した溶液のpHが4.5〜7.5である1〜11のいずれかに記載の総合栄養輸液剤。
13.溶液A、溶液B、溶液C及び溶液Dを混合した時の成分組成において、アミノ酸濃度が25g/L〜55g/Lである1〜12のいずれかに記載の総合栄養輸液剤。
14.非蛋白カロリーと投与窒素量の比が90〜160である13に記載の総合栄養輸液剤。As a result of intensive studies, the inventors have found a method for easily stabilizing trace elements while maintaining the stability of vitamins and eliminating the decrease in iodine content. Furthermore, the iodine content can be easily measured by this method. That is, by mixing copper with a trace element such as iron and iodine with a fat-soluble vitamin, the coexistence of copper ions and iodine ions is avoided. The present invention relates to the following comprehensive nutritional infusion.
1. Solution A, Solution B, Solution C, and Solution D are accommodated in each chamber of a four-chamber container separated by a partition wall that can communicate, Solution A contains reducing sugar and vitamin B1, and Solution B contains amino acids. A comprehensive nutritional infusion, wherein the solution C contains at least one fat-soluble vitamin and iodine selected from vitamin A, vitamin D, vitamin E, and vitamin K, and the solution D contains copper.
2. Solution A, Solution B, Solution C, and Solution D are accommodated in each chamber of a four-chamber container separated by a partition wall that can communicate, Solution A contains reducing sugar and vitamin B1, and Solution B contains amino acids. Solution C contains at least one fat-soluble vitamin and iodine selected from vitamin A, vitamin D, vitamin E, and vitamin K, Solution D contains iron and copper, and Solution A and / or Solution B And / or solution C and / or solution D containing an electrolyte and heat-sterilized.
3. 3. The comprehensive nutritional infusion solution according to 1 or 2, wherein the solution C further contains vitamin C and does not contain vitamin B2.
4). 3. The comprehensive nutritional infusion solution according to 1 or 2, wherein the solution C contains vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, biotin, and folic acid, and does not contain vitamin B2.
5. The comprehensive nutrition infusion solution according to any one of 1 to 4, wherein the concentration of iodine in the solution C is 0.10 mmol / L to 0.25 mmol / L.
6). The comprehensive nutritional infusion solution according to any one of 1 to 5, wherein the solution A further contains an electrolyte containing dipotassium phosphate as phosphorus and citric acid.
7). Solution A further contains vitamin B6, vitamin B12 and nicotinic acids, Solution B further contains vitamin B2 and pantothenic acids, Solution C further comprises vitamin C, vitamin H and folic acid. The comprehensive nutritional infusion preparation described in Crab.
8). Solution A further contains vitamin B6 and vitamin B12, solution B further contains vitamin B2, pantothenic acids and nicotinic acids, and solution C further contains vitamin C, vitamin H and folic acid. A comprehensive nutritional infusion preparation described in 1.
9. The comprehensive nutrition infusion solution according to any one of 1 to 8, wherein the solution D further contains manganese and zinc.
10. The comprehensive nutritional infusion solution according to any one of 1 to 9, wherein the electrolyte is at least one selected from sodium, potassium, magnesium, calcium, chloro, and phosphorus.
11. The comprehensive nutritional infusion solution according to any one of 1 to 10, wherein the vitamin B1 is at least one selected from thiamine, thiamine disulfide, fursultiamine, benfotiamine and salts thereof.
12 The pH of the solution A is 3 to 6, the pH of the solution B, the solution C and the solution D is 5 to 8, and the pH of the solution obtained by mixing the solution A, the solution B, the solution C and the solution D is 4.5 to 7.5 The comprehensive nutrition infusion solution according to any one of -11.
13. The comprehensive nutritional infusion solution according to any one of 1 to 12, wherein the amino acid concentration is 25 g / L to 55 g / L in the component composition when Solution A, Solution B, Solution C, and Solution D are mixed.
14 14. The comprehensive nutritional infusion preparation according to 13, wherein the ratio of non-protein calorie and administration nitrogen amount is 90 to 160.
この方法は、銅イオンとヨウ素イオンが別室に配合されているため、脱酸素状態での銅イオンとヨウ素イオンによる沈殿を防止することができる。更に小容量である溶液Cの室にヨウ素イオンを収容するため、ヨウ素の濃度を高く設定でき、ヨウ素の含量を測定し易い利点がある。また、薬液を酸素含有ガスと共に収容する必要がないため、ポリエチレン・ビニルアルコール共重合体(EVOH)、ポリ塩化ビニリデン(PVDC)などの高いガスバリア性を有する材質を使用することは不要であり、通常の方法で安価に製造することができる。ヨウ素イオンと脂溶性ビタミンは安定に混在することができるため、脂溶性ビタミン及びヨウ素の含量低下が起きない。 In this method, since copper ions and iodine ions are blended in separate chambers, precipitation due to copper ions and iodine ions in a deoxygenated state can be prevented. Further, since iodine ions are accommodated in the chamber of the solution C having a small capacity, there is an advantage that the iodine concentration can be set high and the iodine content can be easily measured. In addition, since it is not necessary to store the chemical with oxygen-containing gas, it is not necessary to use materials with high gas barrier properties such as polyethylene / vinyl alcohol copolymer (EVOH) and polyvinylidene chloride (PVDC). This method can be manufactured at low cost. Since iodine ions and fat-soluble vitamins can be mixed stably, the content of fat-soluble vitamins and iodine does not decrease.
以下、本発明の総合栄養輸液剤を詳細に説明する。
溶液A、溶液B、溶液C及び溶液Dを連通可能な隔壁で隔てられた4室容器の各室に収容した本発明の総合栄養輸液剤は、加熱滅菌時や保存時に各成分が安定に存在するように隔離された各室に適当に配合されている一方で、連通後は、内容物を基本的に外気にさらすことなく無菌状態で混合することができる。
本発明の総合栄養輸液剤における溶液Aは、還元糖及びビタミンB1を基本組成とし、好ましくは亜硫酸及びその塩を含有しない。使用できる糖としては通常輸液剤に用いられる糖であれば特に制限はないが、例えば、ブドウ糖、フルクトース、マルトースが挙げられる。又、ビタミンB1としては、チアミン、チアミンジスルフィド、フルスルチアミン、ベンフォチアミン及びこれらの塩などが挙げられ、塩酸チアミンが好ましい。また好ましくは、溶液Aには更にビタミンB6及びビタミンB12が配合される。ビタミンB6としては、ピリドキシン、ピリドキサール、ピリドキサミン及びこれらの塩などが挙げられ、塩酸ピリドキシンが好ましい。ビタミンB12には例えばシアノコバラミンとその塩が含まれる。
溶液AのpHは、3〜6に調整するのが好ましい。
溶液Aは更に電解質を含むのが好ましく、この場合、リン供給源としてリン酸二カリウムなどのリン酸塩とカルシウム塩を含むことがある。この場合、pH調節剤としてクエン酸を用いると、リン酸カルシウム生成を抑制するため、滅菌時及び長期保存時における製剤の安定性向上の点から好ましい。溶液Aの還元糖及び電解質濃度を高くする場合やpHを5以上とする場合に、クエン酸を用いることが特に望ましい。
溶液Aの液量は、半日〜1日投与用の製剤として、好ましくは400 〜 1400 mlであり、特に好ましくは 400 〜 1100 mlである。Hereinafter, the comprehensive nutrition infusion solution of the present invention will be described in detail.
The comprehensive nutritional infusion solution of the present invention housed in each chamber of a four-chamber container separated by a partition wall capable of communicating Solution A, Solution B, Solution C, and Solution D has stable components during heat sterilization and storage. While properly blended in each of the isolated chambers, the contents can be mixed in aseptic conditions after communication without essentially exposing the contents to the outside air.
Solution A in the comprehensive nutritional infusion preparation of the present invention has a basic composition of reducing sugar and vitamin B1, and preferably does not contain sulfite or a salt thereof. The sugar that can be used is not particularly limited as long as it is a sugar that is usually used for an infusion, and examples thereof include glucose, fructose, and maltose. Examples of vitamin B1 include thiamine, thiamine disulfide, fursultiamine, benfotiamine and their salts, and thiamine hydrochloride is preferred. Preferably, the solution A further contains vitamin B6 and vitamin B12. Examples of vitamin B6 include pyridoxine, pyridoxal, pyridoxamine, and salts thereof, and pyridoxine hydrochloride is preferable. Vitamin B12 includes, for example, cyanocobalamin and its salts.
The pH of the solution A is preferably adjusted to 3-6.
The solution A preferably further contains an electrolyte. In this case, a phosphate salt such as dipotassium phosphate and a calcium salt may be contained as a phosphorus source. In this case, it is preferable to use citric acid as a pH adjuster from the viewpoint of improving the stability of the preparation during sterilization and long-term storage because calcium phosphate production is suppressed. It is particularly desirable to use citric acid when the reducing sugar and electrolyte concentration of the solution A is increased or when the pH is 5 or more.
The amount of the solution A is preferably 400 to 1400 ml, particularly preferably 400 to 1100 ml, as a preparation for half-day to daily administration.
溶液Bはアミノ酸液である。アミノ酸の配合比率は従来のアミノ酸液の配合比率と同様にすることができる。本発明の総合栄養輸液剤において、使用できるアミノ酸としては通常輸液に用いられるアミノ酸であれば特に制限はない。具体的には、L−イソロイシン、L−ロイシン、L−リジン、L−メチオニン、L−フェニルアラニン、L−トレオニン、L−トリプトファン、L−バリン、L−アラニン、L−アルギニン、L−アスパラギン酸、システイン、L−グルタミン酸、L−ヒスチジン、L−プロリン、L−セリン、L−チロシン、グリシンなどが挙げられる。アミノ酸は遊離のアミノ酸のみならず塩であってもよい。このような塩としては例えばL-リジン酢酸塩、L-リジン塩酸塩が挙げられる。更にその一部はアシル体やペプチドであっても良い。このようなアシル体としては例えばアセチルシステインが挙げられる。
溶液Bには、アミノ酸液の安定化のために、亜硫酸塩又は亜硫酸水素塩、例えば、亜硫酸水素ナトリウムを添加することができる。
また、溶液Bには、好ましくは更にビタミンB2及びパンテトン酸類が配合される。ビタミンB2としては、リボフラビン、リボフラビンリン酸エステル及びそのナトリウム塩、フラビンモノヌクレオチドが挙げられ、特にリン酸リボフラビンナトリウムが好ましい。パントテン酸類としては、パントテン酸又はそのカルシウム塩、パンテノールなどが挙げられ、好ましくはパンテノールである。Solution B is an amino acid solution. The mixing ratio of amino acids can be the same as the mixing ratio of conventional amino acid solutions. In the comprehensive nutrition infusion solution of the present invention, the amino acid that can be used is not particularly limited as long as it is an amino acid that is usually used for infusion. Specifically, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, Examples include cysteine, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, and glycine. The amino acid may be a salt as well as a free amino acid. Examples of such salts include L-lysine acetate and L-lysine hydrochloride. Further, some of them may be acyl forms or peptides. An example of such an acyl body is acetylcysteine.
To the solution B, sulfite or bisulfite, for example, sodium bisulfite can be added for stabilization of the amino acid solution.
The solution B preferably further contains vitamin B2 and pantetonic acids. Examples of vitamin B2 include riboflavin, riboflavin phosphate and its sodium salt, and flavin mononucleotide, and sodium riboflavin phosphate is particularly preferable. Examples of pantothenic acids include pantothenic acid or its calcium salt, panthenol, and the like, preferably panthenol.
溶液BのpHは、5 〜 8に調整するのが好ましい。
溶液Bの液量は、半日〜1日投与用の製剤として、好ましくは 200 〜 700 mlであり、特に好ましくは 300 〜 600 mlである。The pH of the solution B is preferably adjusted to 5-8.
The amount of the solution B is preferably 200 to 700 ml, particularly preferably 300 to 600 ml, as a preparation for half-day to daily administration.
A液又はB液に、ニコチン酸類が配合されるのが好ましい。ニコチン酸類としては、ニコチン酸、ニコチン酸アミド、ニコチン酸ナトリウム、ニコチン酸メチルエステルなどが挙げられ、好ましくはニコチン酸アミドである。 It is preferable that nicotinic acids are blended in the liquid A or liquid B. Examples of nicotinic acids include nicotinic acid, nicotinic acid amide, sodium nicotinic acid, and nicotinic acid methyl ester, and nicotinic acid amide is preferable.
溶液CはビタミンA、ビタミンD、ビタミンE、ビタミンKより選ばれる少なくとも1種類以上の脂溶性ビタミンを含有しており、必要に応じて可溶化剤を添加することができる。
ビタミンAとしては、レチノールやそのエステルなどが含まれ、より具体的にはパルミチン酸レチノール、酢酸レチノールなどが挙げられ、パルミチン酸レチノールが好ましい。ビタミンDとしては、ビタミンD2(エルゴカルシフェロール)、ビタミンD3(コレカルシフェロール)及びそれらの活性型などが挙げられ、コレカルシフェロールが好ましい。ビタミンEとしては、トコフェロールとそのエステル、より具体的には酢酸トコフェロール、コハク酸トコフェロールが挙げられ、酢酸トコフェロールが好ましい。ビタミンKとしては、ビタミンK1(フィトナジオン)、ビタミンK2(メナテトレノン)、ビタミンK3(メナジオン)などが挙げられ、フィトナジオンが好ましい。
可溶化剤としては、ポリソルベート80、ポリソルベート20、HCO-60、ポリエチレングリコールなどが挙げられる。また、安定化剤として、ソルビトール、マンニトール、キシリトール、マルチトールなどの糖アルコール、またはグリセリンを添加することができる。
溶液Cにヨウ素を入れることにより、ヨウ素を安定に維持することができる。更に驚くべきことに溶液C内において、ヨウ素の存在によって上記脂溶性ビタミンの含量低下は起きない。又、溶液Cに含有される脂溶性ビタミンは、配合するのに小容量の媒体ですむため、溶液Cの室は小容量であり、ヨウ素の濃度を高く設定できる。それにより甲状腺の機能維持等の観点から重要な、ヨウ素濃度の測定を容易に正確に行うことができる。好ましくは溶液Cにおいてヨウ素濃度(ヨウ化物イオン濃度)は0.027〜1.3mmol/Lであり、特に好ましくは0.10 〜 0.25 mmol/Lである。ヨウ素供給源としては、例えばヨウ化カリウム、ヨウ化ナトリウムなどが挙げられ、ヨウ化カリウムが好ましい。
溶液Cは銅を実質的に含まない。このため脱酸素状態であってもヨウ素の沈殿を生じない。
溶液Cは更にビタミンCを含有し且つビタミンB2を含有しないのが好ましい。ビタミンCとしては、アスコルビン酸、アスコルビン酸ナトリウムなどが挙げられ、アスコルビン酸が好ましい。ビタミンB2の非存在下で、上記脂溶性ビタミン、ヨウ素、及びビタミンCの混合物は特に安定に存在する。
溶液Cは更にビタミンH(ビオチン)や葉酸を含有するのが好ましい。特に、溶液CがビタミンA、ビタミンD、ビタミンE、ビタミンK、ビタミンC、ビタミンH(ビオチン)、及び葉酸を含有し、かつ、ビタミンB2を含有しない場合に、溶液C中のこれら成分の安定性が特に高い。
溶液CのpHは、5 〜 8に調整するのが好ましい。
溶液Cの液量は、半日〜1日投与用の製剤として、好ましくは1〜10mlであり、特に好ましくは2〜8mlである。Solution C contains at least one fat-soluble vitamin selected from vitamin A, vitamin D, vitamin E, and vitamin K, and a solubilizer can be added as necessary.
Vitamin A includes retinol and esters thereof, more specifically, retinol palmitate, retinol acetate, and the like, with retinol palmitate being preferred. Examples of vitamin D include vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol) and active forms thereof, and cholecalciferol is preferable. Examples of vitamin E include tocopherol and its ester, more specifically tocopherol acetate and tocopherol succinate, and tocopherol acetate is preferred. Examples of vitamin K include vitamin K1 (phytonadione), vitamin K2 (menatetrenone), vitamin K3 (menadione), and phytonadione is preferred.
Examples of the solubilizer include polysorbate 80, polysorbate 20, HCO-60, and polyethylene glycol. In addition, sugar alcohols such as sorbitol, mannitol, xylitol, maltitol, or glycerin can be added as a stabilizer.
By putting iodine into the solution C, iodine can be stably maintained. Furthermore, surprisingly, in solution C, the content of the fat-soluble vitamin does not decrease due to the presence of iodine. In addition, since the fat-soluble vitamin contained in the solution C requires a small volume medium to be mixed, the chamber of the solution C has a small volume, and the iodine concentration can be set high. This makes it possible to easily and accurately measure the iodine concentration, which is important from the viewpoint of maintaining the function of the thyroid gland. Preferably in solution C, the iodine concentration (iodide ion concentration) is 0.027 to 1.3 mmol / L, particularly preferably 0.10 to 0.25 mmol / L. Examples of the iodine supply source include potassium iodide and sodium iodide, and potassium iodide is preferable.
Solution C is substantially free of copper. For this reason, no precipitation of iodine occurs even in a deoxygenated state.
Solution C preferably further contains vitamin C and no vitamin B2. Examples of vitamin C include ascorbic acid and sodium ascorbate, and ascorbic acid is preferred. In the absence of vitamin B2, the fat-soluble vitamin, iodine and vitamin C mixture is particularly stable.
Solution C preferably further contains vitamin H (biotin) and folic acid. In particular, when solution C contains vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin H (biotin), and folic acid, and does not contain vitamin B2, the stability of these components in solution C Is particularly high.
The pH of the solution C is preferably adjusted to 5-8.
The amount of the solution C is preferably 1 to 10 ml, particularly preferably 2 to 8 ml, as a preparation for half-day to daily administration.
溶液Dは、銅を含有し、好ましくは鉄、銅の微量元素を含有する。鉄、銅の他にマンガン、亜鉛などの微量元素を含有することが好ましい。
鉄供給源としては、硫酸鉄、塩化第一鉄、塩化第二鉄及びグルコン酸鉄などが挙げられる。銅供給源としては、硫酸銅などが挙げられる。マンガン供給源としては、塩化マンガン、硫酸マンガンなどが挙げられる。亜鉛供給源としては、硫酸亜鉛、塩化亜鉛、グルコン酸亜鉛、乳酸亜鉛、酢酸亜鉛などが挙げられる。
また、溶液Dには必要に応じてコンドロイチン硫酸ナトリウムを添加することができる。The solution D contains copper, and preferably contains iron and copper trace elements. It is preferable to contain trace elements such as manganese and zinc in addition to iron and copper.
Examples of the iron supply source include iron sulfate, ferrous chloride, ferric chloride, and iron gluconate. Examples of the copper supply source include copper sulfate. Examples of the manganese supply source include manganese chloride and manganese sulfate. Examples of the zinc supply source include zinc sulfate, zinc chloride, zinc gluconate, zinc lactate, and zinc acetate.
Further, sodium chondroitin sulfate can be added to the solution D as necessary.
溶液DのpHは、5〜8に調整するのが好ましい。
溶液Dの液量は、半日〜1日投与用の製剤として、好ましくは1〜 10mlであり、特に好ましくは2〜8mlである。
本発明の総合栄養輸液剤は電解質を含有する。電解質は通常の電解質輸液などに用いられているものであれば特に制限されず、ナトリウム、カリウム、カルシウム、マグネシウム、リン、塩素などが挙げられ、水溶液中でイオンを生じさせる無機塩、有機塩などが好ましい。電解質は溶液A乃至Dの何れに含有されていてもよいが、溶液Aに含有されるのが好ましい。なお、電解質は、生体の機能や体液の電解質バランスを維持するために必要である。The pH of the solution D is preferably adjusted to 5-8.
The amount of the solution D is preferably 1 to 10 ml, particularly preferably 2 to 8 ml, as a preparation for half-day to daily administration.
The comprehensive nutrition infusion solution of the present invention contains an electrolyte. The electrolyte is not particularly limited as long as it is used for normal electrolyte infusions, and examples thereof include sodium, potassium, calcium, magnesium, phosphorus, chlorine, and the like, and inorganic salts and organic salts that generate ions in an aqueous solution Is preferred. The electrolyte may be contained in any of the solutions A to D, but is preferably contained in the solution A. The electrolyte is necessary for maintaining the function of the living body and the electrolyte balance of the body fluid.
各溶液に使用されるpH調節剤としては、生理的に許容できるものであれば特に限定されず、例えば有機酸、無機酸、有機塩基、無機塩基を使用することができる。前記有機酸としては、酢酸、クエン酸、乳酸、コハク酸、リンゴ酸などが挙げられ、無機酸としては塩酸、硫酸、リン酸などを挙げることができる。一方、有機塩基としては酢酸ナトリウム、クエン酸ナトリウム、乳酸ナトリウムなどが挙げられ、無機塩基としては水酸化アルカリ金属(例えば水酸化ナトリウム)などを挙げることができる。
中心静脈用輸液は、1日投与量として、総水分量を1400〜1800 mLに抑えつつ、アミノ酸を45〜75 gとし、非蛋白カロリーと投与窒素量の比率(NPC/N比)を 90〜160の範囲内にすることが好ましく(特開2008−266288)、本発明の総合栄養輸液剤は、好ましくは、そのような輸液を提供するのに好適な還元糖及びアミノ酸濃度を有する。本発明の総合輸液製剤は、消化器系又は循環器系の術後の、侵襲時の患者に使用することができ、さらに嚥下障害や脳梗塞後遺症など、経口・経管栄養摂取不能又は不十分で、エネルギー要求量が低下している患者、例えば高齢者などにも使用できる。
また、本発明の総合輸液製剤に含まれるビタミン類は、米国医師会の推奨するビタミン必要量を確保できるビタミン濃度であることが好ましい。例えば、ビタミンB1(チアミン)6.0 mg/日 、ビタミンC 200 mg/日である。
本発明の総合栄養輸液剤において、溶液A、溶液B、溶液C及び溶液Dを混合した溶液の成分組成において以下が好ましい:
ブドウ糖を50〜400g/L、更に好ましくは、100〜250g/L。The pH adjuster used in each solution is not particularly limited as long as it is physiologically acceptable, and for example, organic acids, inorganic acids, organic bases, and inorganic bases can be used. Examples of the organic acid include acetic acid, citric acid, lactic acid, succinic acid, and malic acid. Examples of the inorganic acid include hydrochloric acid, sulfuric acid, and phosphoric acid. On the other hand, examples of the organic base include sodium acetate, sodium citrate, and sodium lactate, and examples of the inorganic base include alkali metal hydroxide (for example, sodium hydroxide).
Central venous infusions have a total daily water content of 1400 to 1800 mL, amino acids of 45 to 75 g, and a ratio of non-protein calories to dose of nitrogen (NPC / N ratio) of 90 to It is preferable to be within the range of 160 (Japanese Patent Laid-Open No. 2008-266288), and the comprehensive nutritional infusion solution of the present invention preferably has a reducing sugar and amino acid concentration suitable for providing such an infusion solution. The comprehensive infusion preparation of the present invention can be used for patients at the time of invasion after surgery of the digestive system or circulatory system, and ingestion or inadequate oral or tube nutrition such as dysphagia or sequelae of cerebral infarction Therefore, it can also be used for patients whose energy requirements are low, such as elderly people.
Moreover, it is preferable that the vitamins contained in the comprehensive infusion preparation of the present invention have a vitamin concentration that can ensure the required amount of vitamin recommended by the American Medical Association. For example, vitamin B1 (thiamine) 6.0 mg / day, vitamin C 200 mg / day.
In the comprehensive nutritional infusion solution of the present invention, the component composition of the solution obtained by mixing the solution A, the solution B, the solution C, and the solution D is preferably the following:
Glucose is 50 to 400 g / L, more preferably 100 to 250 g / L.
アミノ酸総量として、25.0〜55.0 g/L。
(各アミノ酸(遊離体として換算))
L-イソロイシンを0.2〜14.0g/L、更に好ましくは1.0〜6.0g/L、
L-ロイシンを0.4〜20.0g/L、更に好ましくは1.0〜10.0g/L、
L-リジンを0.2〜14.0g/L、更に好ましくは1.0〜5.0g/L、
L-メチオニンを0.1〜8.0g/L、更に好ましくは0.5〜5.0g/L、
L-フェニルアラニンを0.2〜12.0g/L、更に好ましくは1.0〜5.0g/L、
L-トレオニンを0.1〜8.0g/L、更に好ましくは0.5〜4.0g/L、
L-トリプトファンを0.04〜3.0g/L、更に好ましくは0.2〜1.5g/L、
L-バリンを0.1〜16.0g/L、更に好ましくは1.0〜6.0g/L、
L-アラニンを0.2〜14.0g/L、更に好ましくは1.0〜6.0g/L、
L-アルギニンを0.2〜14.0g/L、更に好ましくは1.0〜7.0g/L、
L-アスパラギン酸を0.01〜4.0g/L、更に好ましくは0.1〜2.0g/L、
L-グルタミン酸を0.01〜6.0g/L、更に好ましくは0.1〜2.0g/L、
L-ヒスチジンを0.1〜8.0g/L、更に好ましくは0.5〜5.0g/L、
L-プロリンを0.1〜10.0g/L、更に好ましくは0.5〜5.0g/L、
L-セリンを0.1〜6.0g/L、更に好ましくは0.2〜3.0g/L、
L-チロシンを0.01〜2.0g/L、更に好ましくは0.05〜1.0g/L、
グリシンを0.1〜12.0g/L、更に好ましくは1.0〜5.0g/L、
L-システインを0.01〜2.0g/L、更に好ましくは0.1〜2.0g/L。The total amount of amino acids is 25.0-55.0 g / L.
(Each amino acid (converted as a free form))
L-isoleucine 0.2-14.0 g / L, more preferably 1.0-6.0 g / L,
L-leucine is 0.4-20.0 g / L, more preferably 1.0-0.0 g / L,
L-lysine is 0.2-14.0 g / L, more preferably 1.0-5.0 g / L,
L-methionine 0.1-8.0 g / L, more preferably 0.5-5.0 g / L,
L-phenylalanine 0.2-12.0 g / L, more preferably 1.0-5.0 g / L,
L-threonine 0.1-8.0 g / L, more preferably 0.5-4.0 g / L,
L-tryptophan 0.04-3.0 g / L, more preferably 0.2-1.5 g / L,
L-valine 0.1-16.0 g / L, more preferably 1.0-6.0 g / L,
L-alanine 0.2-14.0 g / L, more preferably 1.0-6.0 g / L,
L-arginine 0.2-14.0 g / L, more preferably 1.0-7.0 g / L,
L-aspartic acid 0.01-4.0 g / L, more preferably 0.1-2.0 g / L,
L-glutamic acid 0.01-6.0 g / L, more preferably 0.1-2.0 g / L,
L-histidine 0.1-8.0 g / L, more preferably 0.5-5.0 g / L,
L-proline 0.1-10.0 g / L, more preferably 0.5-5.0 g / L,
L-serine 0.1-6.0 g / L, more preferably 0.2-3.0 g / L,
L-tyrosine 0.01-2.0 g / L, more preferably 0.05-1.0 g / L,
0.1 to 12.0 g / L of glycine, more preferably 1.0 to 5.0 g / L,
L-cysteine is 0.01 to 2.0 g / L, more preferably 0.1 to 2.0 g / L.
(ビタミン類)
ビタミンAを500 〜 5000 IU/L、更に好ましくは、1000 〜 4000 IU/L、
ビタミンD(コレカルシフェロールとして)を1.0〜20 μg/L、更に好ましくは、1.0〜10 μg/L、
ビタミンE(酢酸トコフェロールとして)を1.0〜30 mg/L、更に好ましくは、2.0〜15 mg/L、
ビタミンK(フィトナシ゛オンとして)を0.1〜5.0mg/L、更に好ましくは、0.2〜2.5mg/L、
ビタミンB1(塩酸チアミンとして)を0.5〜50mg/L、更に好ましくは、1.0〜20mg/L、
ビタミンB2(リホ゛フラヒ゛ンとして)を0.5〜10mg/L、更に好ましくは、1.0〜5.0mg/L、
ビタミンB6(塩酸ヒ゜リト゛キシンとして)を0.5〜10mg/L、更に好ましくは、1.0〜5.0mg/L、
ビタミンB12(シアノコハ゛ラミンとして)を1.0〜20μg/L、更に好ましくは、1.0〜10μg/L、
ニコチン酸類(ニコチン酸アミト゛として)を5.0〜80mg/L、更に好ましくは、10〜50mg/L、
ビタミンC(アスコルヒ゛ン酸として)を25〜300mg/L、更に好ましくは、25〜200mg/L、
パントテン酸類(ハ゜ンテノールとして)を1.0〜30mg/L、更に好ましくは、1.0〜20mg/L、
葉酸を50〜500μg/L、更に好ましくは、100〜400μg/L、
ビタミンH(ビオチン)を10〜200μg/L、更に好ましくは、10〜100μg/L。(Vitamins)
Vitamin A 500-5000 IU / L, more preferably 1000-4000 IU / L,
Vitamin D (as cholecalciferol) 1.0-20 μg / L, more preferably 1.0-10 μg / L,
Vitamin E (as tocopherol acetate) 1.0-30 mg / L, more preferably 2.0-15 mg / L,
Vitamin K (as phytonadione) 0.1-5.0 mg / L, more preferably 0.2-2.5 mg / L,
Vitamin B1 (as thiamine hydrochloride) 0.5-50 mg / L, more preferably 1.0-20 mg / L,
Vitamin B2 (as riboflavin) 0.5-10mg / L, more preferably 1.0-5.0mg / L,
0.5-10 mg / L of vitamin B6 (as hypoxin hydrochloride), more preferably 1.0-5.0 mg / L,
Vitamin B12 (as cyanocobalamin) 1.0-20 μg / L, more preferably 1.0-10 μg / L,
Nicotinic acid (as nicotinic acid amide) 5.0-80 mg / L, more preferably 10-50 mg / L,
Vitamin C (as ascorbic acid) 25-300 mg / L, more preferably 25-200 mg / L,
Pantothenic acids (as huntenol) 1.0-30 mg / L, more preferably 1.0-20 mg / L,
50 to 500 μg / L of folic acid, more preferably 100 to 400 μg / L,
Vitamin H (biotin) is 10 to 200 μg / L, more preferably 10 to 100 μg / L.
(微量元素)
鉄を5 〜 100μmol/L、
銅を1 〜 20μmol/L、
マンガンを0.1 〜 5μmol/L、
亜鉛を5 〜 150μmol/L、
ヨウ素を0.1 〜 5μmol/L。(Trace element)
5-100 μmol / L of iron,
1-20 μmol / L of copper,
0.1 to 5 μmol / L of manganese,
5 to 150 μmol / L of zinc,
Iodine 0.1-5 μmol / L.
(電解質)
ナトリウムイオンを25〜75 mEq/L、
カリウムイオンを15〜45mEq/L、
カルシウムイオン を2.5〜10mEq/L、
マグネシウムイオンを2.5〜10mEq/L、
塩素イオンを2.5〜75mEq/L、
リンを0〜20mmol/L。(Electrolytes)
25-75 mEq / L of sodium ion,
15-45 mEq / L of potassium ion,
Calcium ions 2.5 to 10 mEq / L,
2.5-10 mEq / L of magnesium ion,
2.5-75 mEq / L of chloride ion,
Phosphorus from 0 to 20 mmol / L.
又、本発明の総合栄養輸液剤において、溶液A、溶液B、溶液C及び溶液Dが混合した溶液のpHは、4.5〜7.5となるようにするのが好ましい。 Moreover, in the comprehensive nutrition infusion solution of the present invention, the pH of the solution obtained by mixing the solution A, the solution B, the solution C and the solution D is preferably 4.5 to 7.5.
連通可能な隔壁で隔てられた4室容器としては、公知の容器を使用できる。このうち隔壁が、易剥離シールで構成された輸液バッグが、連通作業が簡単なため好ましい。輸液バッグの素材は、例えばポリエチレン、ポリプロピレン、ポリブテンのようなポリオレフィン、エチレン・プロピレン共重合体、架橋エチレン・酢酸ビニル共重合体、これらの積層体等が適当である。 A well-known container can be used as a four-chamber container separated by a partition wall that can communicate. Of these, an infusion bag in which the partition wall is constituted by an easily peelable seal is preferable because the communication work is simple. Suitable materials for the infusion bag are, for example, polyolefins such as polyethylene, polypropylene and polybutene, ethylene / propylene copolymers, crosslinked ethylene / vinyl acetate copolymers, and laminates thereof.
溶液Cの容器材質は、脂溶性ビタミンの吸着を抑制する材質が望ましく、例えば環状ポリオレフィン、ポリエチレンテレフタレート、ポリアクリロニトリルなどが挙げられる。また、容器の表面積は小さい方が望ましい。なお、積層体として、溶液Cに接する最内層をこれらの材質にすることもできる。 The container material of the solution C is desirably a material that suppresses the adsorption of fat-soluble vitamins, and examples thereof include cyclic polyolefin, polyethylene terephthalate, polyacrylonitrile, and the like. Further, it is desirable that the surface area of the container is small. In addition, as a laminated body, the innermost layer which contact | connects the solution C can also be made from these materials.
また、溶液Dの微量元素と、溶液Bの含硫アミノ酸から生成するガスとが反応して含量低下を生じるのを防ぐ観点から、溶液Dの容器材質として、ガス難透過性の材質が望ましく、例えば環状ポリオレフィン、ポリエチレンテレフタレート、ポリアクリロニトリルなどが挙げられる。なお溶液Cと溶液Dが同じ材質であれば、製造工程を簡素化できる利点がある。 In addition, from the viewpoint of preventing a decrease in content due to a reaction between a trace element of the solution D and a gas generated from the sulfur-containing amino acid of the solution B, a material that is hardly permeable to gas is desirable as a container material of the solution D. Examples thereof include cyclic polyolefin, polyethylene terephthalate, polyacrylonitrile and the like. In addition, if the solution C and the solution D are the same material, there exists an advantage which can simplify a manufacturing process.
薬液を充填した容器は、常法により脱酸素剤と共に遮光性を有するガス非透過性フィルムからなる外包装材に封入するのが望ましい。遮光性を有するガス非透過性の外包装材としては、一般に汎用されている、アルミ箔、アルミ蒸着フィルム等があげられる。また、遮光性を有する層とガス非透過性を有する層を組み合わせることも可能であり、遮光性を有する層としては、遮光性能として許容される透過率をクリアできるものであれば特に限定されないが、例えば黒色印刷を施した汎用樹脂フィルムを用いることができる。また、ガス非透過性の外包装材としては、ポリエチレンテレフタレート、ポリエチレンナフタレート、エチレン・ビニルアルコール共重合体、ポリ塩化ビニリデン、ポリアクリロニトリル、ポリアミド、アルミナ蒸着フィルム、シリカ蒸着フィルム等を選択することが可能であり、1種若しくは数種を組み合わせて使用することも可能である。
脱酸素剤としては、水酸化鉄、酸化鉄、炭化鉄等の鉄化合物を主成分とするものが用いられる。市販品としては、エージレス(三菱ガス化学社製)、モジュラン(日本化薬社製)、セキュール(日本曹達社製)等があげられる。
輸液バッグと外包装容器の間の空間は窒素等の不活性ガスで充填されていることが好ましい。
これらにより、保存期間中、各液を含めた外包装材内部を脱酸素状態にすることができる。It is desirable to enclose the container filled with the chemical solution in an outer packaging material made of a gas non-permeable film having a light shielding property together with an oxygen scavenger by a conventional method. Examples of the gas non-permeable outer packaging material having light shielding properties include aluminum foil and aluminum vapor deposition film which are generally used. In addition, it is possible to combine a light-shielding layer and a gas non-permeable layer, and the light-shielding layer is not particularly limited as long as it can clear the transmittance allowed as the light shielding performance. For example, a general-purpose resin film subjected to black printing can be used. Further, as the gas non-permeable outer packaging material, polyethylene terephthalate, polyethylene naphthalate, ethylene / vinyl alcohol copolymer, polyvinylidene chloride, polyacrylonitrile, polyamide, alumina vapor deposition film, silica vapor deposition film, etc. can be selected. It is possible to use one kind or a combination of several kinds.
As the oxygen scavenger, those containing iron compounds such as iron hydroxide, iron oxide and iron carbide as main components are used. Commercially available products include AGELESS (Mitsubishi Gas Chemical Co., Ltd.), Modulan (Nippon Kayaku Co., Ltd.), Secur (Nippon Soda Co., Ltd.) and the like.
The space between the infusion bag and the outer packaging container is preferably filled with an inert gas such as nitrogen.
Thus, the inside of the outer packaging material including each liquid can be deoxygenated during the storage period.
次に、実施例を挙げて本発明を更に詳細に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES Next, although an Example is given and this invention is demonstrated further in detail, this invention is not limited to these.
(実施例1)
ブドウ糖及び電解質を注射用水に溶解後、ビタミンB1(塩酸チアミン)、ビタミンB6(塩酸ピリドキシン)、ニコチン酸アミド及びビタミンB12(シアノコバラミン)等を溶解した。酢酸を用いてpH4.5に調節後、全量を500mLとし、メンブランフィルター(0.2μm)を用いて濾過し、表1に示した組成の溶液Aを調製した。Example 1
After dissolving glucose and electrolyte in water for injection, vitamin B1 (thiamine hydrochloride), vitamin B6 (pyridoxine hydrochloride), nicotinamide, vitamin B12 (cyanocobalamin) and the like were dissolved. After adjusting the pH to 4.5 using acetic acid, the total volume was adjusted to 500 mL, followed by filtration using a membrane filter (0.2 μm) to prepare Solution A having the composition shown in Table 1.
各アミノ酸を注射用水に溶解後、ビタミンB2(リン酸リボフラビンナトリウム)及びパンテノールを溶解した。この溶液に安定化剤として亜硫酸水素ナトリウムを溶解した。酢酸を用いてpH6.5に調節後、全量を300mLとし、メンブランフィルター(0.2μm)を用いて濾過し、表1に示した組成の溶液Bを調製した。 After dissolving each amino acid in water for injection, vitamin B2 (phosphoflavin sodium phosphate) and panthenol were dissolved. Sodium bisulfite was dissolved in this solution as a stabilizer. After adjusting the pH to 6.5 with acetic acid, the total volume was adjusted to 300 mL, and filtration was performed using a membrane filter (0.2 μm) to prepare Solution B having the composition shown in Table 1.
ビタミンA(パルミチン酸レチノール)、ビタミンD3(コレカルシフェロール)、ビタミンE(酢酸トコフェロール)及びビタミンK1(フィトナジオン)をポリソルベート20及びポリソルベート80により可溶化した後、注射用水に溶解した。更にヨウ化カリウム、ソルビトール、ビタミンC(アスコルビン酸)、ビタミンH(ビオチン)及び葉酸を溶解した。水酸化ナトリウムを用いてpH6.0に調節後、全量を3mLとし、メンブランフィルター(0.2μm)を用いて濾過し、表1に示した組成の溶液Cを調製した。 Vitamin A (retinol palmitate), vitamin D3 (cholecalciferol), vitamin E (tocopherol acetate) and vitamin K1 (phytonadione) were solubilized with polysorbate 20 and polysorbate 80, and then dissolved in water for injection. Furthermore, potassium iodide, sorbitol, vitamin C (ascorbic acid), vitamin H (biotin) and folic acid were dissolved. After adjusting the pH to 6.0 using sodium hydroxide, the total volume was adjusted to 3 mL, followed by filtration using a membrane filter (0.2 μm) to prepare Solution C having the composition shown in Table 1.
コンドロイチン硫酸ナトリウムを注射用水に溶解した水溶液に、塩化第二鉄を注射用水に溶解した水溶液と水酸化ナトリウムを注射用水に溶解した水溶液を交互に添加し、鉄コロイド溶液を調製した。この溶液に、塩化マンガン、硫酸亜鉛、硫酸銅を溶解した。水酸化ナトリウムを用いてpH5.7に調節後、全量を3mLとし、メンブランフィルター(0.2μm)を用いて濾過し、表1に示した組成の溶液Dを調製した。 An iron colloid solution was prepared by alternately adding an aqueous solution in which ferric chloride was dissolved in water for injection and an aqueous solution in which sodium hydroxide was dissolved in water for injection into an aqueous solution in which sodium chondroitin sulfate was dissolved in water for injection. Manganese chloride, zinc sulfate, and copper sulfate were dissolved in this solution. After adjusting the pH to 5.7 using sodium hydroxide, the total volume was adjusted to 3 mL, followed by filtration using a membrane filter (0.2 μm) to prepare a solution D having the composition shown in Table 1.
溶液A、溶液B、溶液C及び溶液Dを連通可能な隔壁で隔てられた4室容器の各室に、それぞれ500mL、300mL、3mL及び3mL充填し、空間部を窒素置換後、密封した。常法に従い高圧蒸気滅菌を行った後、製剤を脱酸素剤(エージレス、三菱ガス化学(株)製)と共にガス非透過性フィルムからなる外包装材に封入し、本発明の総合栄養輸液剤を得た。溶液A、溶液B、溶液C及び溶液DのpHはそれぞれ約4.5、6.5、6.0及び5.6であった。
なお溶液A〜Dを混合した組成のpHは5.4であった。500 mL, 300 mL, 3 mL, and 3 mL were filled in each chamber of a four-chamber container separated by a partition wall through which Solution A, Solution B, Solution C, and Solution D can communicate, and the space portion was sealed with nitrogen and sealed. After autoclaving according to a conventional method, the preparation is enclosed in an outer packaging material made of a gas-impermeable film together with an oxygen scavenger (ageless, manufactured by Mitsubishi Gas Chemical Co., Ltd.). Obtained. The pH of solution A, solution B, solution C, and solution D were about 4.5, 6.5, 6.0, and 5.6, respectively.
In addition, pH of the composition which mixed solution AD was 5.4.
(実施例2)
実施例1と同様にして、表1に示した組成の溶液A、溶液B、溶液C及び溶液Dを調製する。溶液A、溶液B、溶液C及び溶液Dを連通可能な隔壁で隔てられた4室容器の各室に、それぞれ600mL、300mL、3mL及び3mL充填し、空間部を窒素置換後、密封した。常法に従い高圧蒸気滅菌を行った後、製剤を脱酸素剤(エージレス、三菱ガス化学(株)製)と共にガス非透過性フィルムからなる外包装材に封入し、本発明の総合栄養輸液剤を得た。溶液A、溶液B、溶液C及び溶液DのpHはそれぞれ約4.5、6.5、6.0及び5.6であった。(Example 2)
In the same manner as in Example 1, solutions A, B, C and D having the compositions shown in Table 1 are prepared. 600 mL, 300 mL, 3 mL, and 3 mL were filled in each chamber of a four-chamber container separated by a partition wall that can communicate Solution A, Solution B, Solution C, and Solution D, respectively, and the space was replaced with nitrogen and sealed. After autoclaving according to a conventional method, the preparation is enclosed in an outer packaging material made of a gas-impermeable film together with an oxygen scavenger (ageless, manufactured by Mitsubishi Gas Chemical Co., Ltd.). Obtained. The pH of solution A, solution B, solution C, and solution D were about 4.5, 6.5, 6.0, and 5.6, respectively.
(実施例3)
実施例1と同様にして、表1に示した組成の溶液A、溶液B、溶液C及び溶液Dを調製した。但し、溶液AのpH調節剤はクエン酸を使用した。溶液A、溶液B、溶液C及び溶液Dを連通可能な隔壁で隔てられた4室容器の各室に、それぞれ500mL、300mL、3mL及び3mL充填し、空間部を窒素置換後、密封した。常法に従い高圧蒸気滅菌を行った後、製剤を脱酸素剤(エージレス、三菱ガス化学(株)製)と共にガス非透過性フィルムからなる外包装材に封入し、本発明の総合栄養輸液剤を得た。溶液A、溶液B、溶液C及び溶液DのpHはそれぞれ約4.5、6.5、6.0及び5.6であった。なお溶液A〜Dを混合した組成のpHは5.4であった。(Example 3)
In the same manner as in Example 1, solutions A, B, C and D having the compositions shown in Table 1 were prepared. However, citric acid was used as the pH adjuster of Solution A. 500 mL, 300 mL, 3 mL, and 3 mL were filled in each chamber of a four-chamber container separated by a partition wall through which Solution A, Solution B, Solution C, and Solution D can communicate, and the space portion was sealed with nitrogen and sealed. After autoclaving according to a conventional method, the preparation is enclosed in an outer packaging material made of a gas-impermeable film together with an oxygen scavenger (ageless, manufactured by Mitsubishi Gas Chemical Co., Ltd.). Obtained. The pH of solution A, solution B, solution C, and solution D were about 4.5, 6.5, 6.0, and 5.6, respectively. In addition, pH of the composition which mixed solution AD was 5.4.
(比較例1)
実施例1と同様にして、表1に示した組成の溶液A、溶液B、溶液C及び溶液Dを調製した。溶液A、溶液B、溶液C及び溶液Dを連通可能な隔壁で隔てられた4室容器の各室に、それぞれ500mL、300mL、3mL及び3mL充填し、空間部を窒素置換後、密封した。常法に従い高圧蒸気滅菌を行った後、製剤を脱酸素剤(エージレス、三菱ガス化学(株)製)と共にガス非透過性フィルムからなる外包装材に封入し、比較例1の総合栄養輸液剤を得た。溶液A、溶液B、溶液C及び溶液DのpHはそれぞれ約4.5、6.5、6.0及び5.6であった。(Comparative Example 1)
In the same manner as in Example 1, solutions A, B, C and D having the compositions shown in Table 1 were prepared. 500 mL, 300 mL, 3 mL, and 3 mL were filled in each chamber of a four-chamber container separated by a partition wall through which Solution A, Solution B, Solution C, and Solution D can communicate, and the space portion was sealed with nitrogen and sealed. After autoclaving according to a conventional method, the preparation is enclosed in an outer packaging material made of a gas-impermeable film together with an oxygen scavenger (ageless, manufactured by Mitsubishi Gas Chemical Co., Ltd.). Got. The pH of solution A, solution B, solution C, and solution D were about 4.5, 6.5, 6.0, and 5.6, respectively.
(試験例1)
上記実施例1及び比較例1で調製した総合栄養輸液剤を40℃75%RHに1箇月間保存した後の微量元素の含量を測定した。結果を表2に示す。なお、含量は組成に対する百分率で示した。(Test Example 1)
The contents of trace elements after the total nutrient solution prepared in Example 1 and Comparative Example 1 were stored at 40 ° C. and 75% RH for 1 month were measured. The results are shown in Table 2. The content is expressed as a percentage of the composition.
表2の結果より、実施例1は比較例1に比較して40℃75%RHに1箇月間保存後においても微量元素の含量低下が小さく、長期間安定であることが明らかとなった。 From the results shown in Table 2, it was revealed that Example 1 had a small decrease in the content of trace elements and was stable for a long time even after storage at 40 ° C. and 75% RH for 1 month as compared with Comparative Example 1.
また、実施例1及び比較例1で調製した総合栄養輸液剤を40℃75%RHに1箇月間保存した後のビタミン類の含量を測定した。結果を表3に示す。なお、含量は組成に対する百分率で示した。 In addition, the content of vitamins after the comprehensive nutritional infusion prepared in Example 1 and Comparative Example 1 was stored at 40 ° C. and 75% RH for 1 month was measured. The results are shown in Table 3. The content is expressed as a percentage of the composition.
表3の結果より、実施例1は40℃75%RHに1箇月間保存後においてもビタミン類の含量低下が小さく、本発明の総合栄養輸液剤はビタミン類が長期間安定であることが明らかとなった。又、実施例1と比較例1の比較から、溶液Cに含有されるビタミン類(A, D3, E, K1, C, 葉酸、ビオチン)は、溶液Cがヨウ素を含んでいても、含まない場合と同様に安定であることが明らかとなった。(なお、溶液A、Bの組成は、実施例1と比較例1で同じであり、それらに含有されるビタミンの安定性には両者で差が無い。) From the results of Table 3, it is clear that Example 1 shows a small decrease in vitamin content even after storage at 40 ° C. and 75% RH for one month, and that the comprehensive nutrition infusion solution of the present invention is stable in vitamins for a long period of time. It became. From the comparison between Example 1 and Comparative Example 1, the vitamins (A, D3, E, K1, C, folic acid, biotin) contained in the solution C are not included even if the solution C contains iodine. It was found to be as stable as the case. (The compositions of the solutions A and B are the same in Example 1 and Comparative Example 1, and there is no difference between the two in terms of the stability of vitamins contained therein.)
(試験例2)
実施例3で調製した総合栄養輸液剤を40℃75%RHに1箇月間保存した後のビタミン類の含量を測定した。結果を表4に示す。なお、含量は組成に対する百分率で示した。ニコチン酸アミドがA溶液でなくB溶液に含有されている点などで実施例3は実施例1と異なるが、実施例3においても実施例1と同様に、溶液A、B、及びCに含有されるビタミン類が長期間安定であった。(Test Example 2)
The content of vitamins was measured after the comprehensive nutritional infusion prepared in Example 3 was stored at 40 ° C. and 75% RH for one month. The results are shown in Table 4. The content is expressed as a percentage of the composition. Example 3 is different from Example 1 in that nicotinic acid amide is contained in the B solution instead of the A solution. However, in Example 3, as in Example 1, it is contained in the solutions A, B, and C. The vitamins that were made were stable for a long time.
なお実施例1乃至3中の溶液C中のヨウ素は、例えばUV検出器を使用したHPLC法を使用して、薬液の濃縮を行わずに容易に濃度を測定することができる。 The concentration of iodine in the solution C in Examples 1 to 3 can be easily measured without concentration of the chemical solution using, for example, an HPLC method using a UV detector.
本発明は、還元糖、アミノ酸、電解質、ビタミン及び微量元素を含有し、ビタミン類及び微量元素が長期に安定な総合栄養輸液剤を提供することができる。 INDUSTRIAL APPLICABILITY The present invention can provide a comprehensive nutritional infusion that contains reducing sugars, amino acids, electrolytes, vitamins, and trace elements, and vitamins and trace elements are stable for a long period of time.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010534800A JP5631737B2 (en) | 2008-10-22 | 2009-10-19 | Total nutritional fluid |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008271464 | 2008-10-22 | ||
JP2008271464 | 2008-10-22 | ||
PCT/JP2009/067994 WO2010047302A1 (en) | 2008-10-22 | 2009-10-19 | Combination nutritional infusion |
JP2010534800A JP5631737B2 (en) | 2008-10-22 | 2009-10-19 | Total nutritional fluid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014134047A Division JP5828019B2 (en) | 2008-10-22 | 2014-06-30 | Total nutritional fluid |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2010047302A1 true JPWO2010047302A1 (en) | 2012-03-22 |
JP5631737B2 JP5631737B2 (en) | 2014-11-26 |
Family
ID=42119341
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010534800A Active JP5631737B2 (en) | 2008-10-22 | 2009-10-19 | Total nutritional fluid |
JP2014134047A Active JP5828019B2 (en) | 2008-10-22 | 2014-06-30 | Total nutritional fluid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014134047A Active JP5828019B2 (en) | 2008-10-22 | 2014-06-30 | Total nutritional fluid |
Country Status (3)
Country | Link |
---|---|
JP (2) | JP5631737B2 (en) |
TW (1) | TWI474840B (en) |
WO (1) | WO2010047302A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5568272B2 (en) * | 2009-09-29 | 2014-08-06 | テルモ株式会社 | Lipid-containing vitamin-containing liquid containing iodine |
CN106924181A (en) * | 2010-05-07 | 2017-07-07 | Ea制药株式会社 | It is mixed with the peripheral vein administrable nutrition infusion of vitamin |
JP6235779B2 (en) * | 2012-03-28 | 2017-11-22 | 株式会社コーセー | Folic acid-containing composition and method for stabilizing folic acid |
WO2015119183A1 (en) * | 2014-02-05 | 2015-08-13 | 協和発酵キリン株式会社 | Liquid drug containing active vitamin d3 or derivative thereof |
JP6771333B2 (en) * | 2015-08-07 | 2020-10-21 | テルモ株式会社 | Iron-containing injectable preparation |
JP6952468B2 (en) * | 2017-01-31 | 2021-10-20 | 中外製薬株式会社 | Aqueous pharmaceutical composition containing a vitamin D compound |
JP6925148B2 (en) * | 2017-03-28 | 2021-08-25 | テルモ株式会社 | Iron-containing infusion |
JP7188961B2 (en) * | 2018-09-28 | 2022-12-13 | テルモ株式会社 | iron-containing infusion |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11158061A (en) * | 1997-09-25 | 1999-06-15 | Otsuka Pharmaceut Factory Inc | Infusion solution for central vein administration |
JP2003160501A (en) * | 2001-11-21 | 2003-06-03 | Otsuka Pharmaceut Factory Inc | Infusion preparation containing a trace of metal |
JP2006117586A (en) * | 2004-10-21 | 2006-05-11 | Otsuka Pharmaceut Factory Inc | Complex infusion preparation |
JP2006124287A (en) * | 2004-10-26 | 2006-05-18 | Otsuka Pharmaceut Factory Inc | Multiple infusion preparation |
JP2009225448A (en) * | 2008-03-18 | 2009-10-01 | Toshiba Corp | Image reading apparatus and image reading method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2990686B2 (en) * | 1994-11-17 | 1999-12-13 | 田辺製薬株式会社 | Total infusion containing water-soluble vitamin B |
-
2009
- 2009-10-14 TW TW098134787A patent/TWI474840B/en not_active IP Right Cessation
- 2009-10-19 WO PCT/JP2009/067994 patent/WO2010047302A1/en active Application Filing
- 2009-10-19 JP JP2010534800A patent/JP5631737B2/en active Active
-
2014
- 2014-06-30 JP JP2014134047A patent/JP5828019B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11158061A (en) * | 1997-09-25 | 1999-06-15 | Otsuka Pharmaceut Factory Inc | Infusion solution for central vein administration |
JP2003160501A (en) * | 2001-11-21 | 2003-06-03 | Otsuka Pharmaceut Factory Inc | Infusion preparation containing a trace of metal |
JP2006117586A (en) * | 2004-10-21 | 2006-05-11 | Otsuka Pharmaceut Factory Inc | Complex infusion preparation |
JP2006124287A (en) * | 2004-10-26 | 2006-05-18 | Otsuka Pharmaceut Factory Inc | Multiple infusion preparation |
JP2009225448A (en) * | 2008-03-18 | 2009-10-01 | Toshiba Corp | Image reading apparatus and image reading method |
Also Published As
Publication number | Publication date |
---|---|
TW201021851A (en) | 2010-06-16 |
JP5828019B2 (en) | 2015-12-02 |
JP5631737B2 (en) | 2014-11-26 |
TWI474840B (en) | 2015-03-01 |
JP2014221787A (en) | 2014-11-27 |
WO2010047302A1 (en) | 2010-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5828019B2 (en) | Total nutritional fluid | |
JP6766112B2 (en) | Method for stabilizing vitamin C in nutrient infusion solution for hyperbaric vapor sterilization for peripheral intravenous administration | |
KR100570537B1 (en) | Vitamin d solution holder and containers for transfusions | |
EP2554151B1 (en) | Aseptic combination preparation | |
JP4162306B2 (en) | Infusion for central venous administration | |
JP4101418B2 (en) | Total nutritional fluid | |
JP2004001900A (en) | Method for stabilizing vitamins in transfusion for central venous administration | |
JP3771644B2 (en) | Peripheral intravenous infusion | |
JP2003160501A (en) | Infusion preparation containing a trace of metal | |
JP4488907B2 (en) | Method for producing medical double packaging preparation and medical double packaging preparation | |
JP2006020657A (en) | Trace element-blended infusion preparation | |
JP2004189677A (en) | Transfusion preparation | |
JP2006083164A (en) | Transfusion product | |
JP3824716B2 (en) | Infusion for central venous administration | |
JP7403891B2 (en) | Infusion products | |
JP2008195737A (en) | Infusion preparation containing trace of metal | |
JPH10203959A (en) | Infusion administered into central vein | |
JPWO2010104023A1 (en) | Peripheral intravenous infusion containing a sugar solution that contains vitamin B1 stably | |
JP2010090039A (en) | One-pack infusion preparation for peripheral intravenous administration, containing reducing sugar and amino acid | |
JP2020050639A (en) | Iron-containing infusion | |
JP2014058544A (en) | Infusion preparation for peripheral intravenous administration | |
JP2005053872A (en) | Sugar electrolyte maintenance transfusion solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121002 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130719 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140623 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140930 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141008 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5631737 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |